Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:02:21.782Z.
Calculation as of: 2026-10-06T18:02:21.782Z.
Quote observation: 2026-10-06T17:58:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$242.54M
PS Ratio
57.53
TTM Avg
46.85
3Y Avg
41.58
5Y Avg
41.58
Market Cap
$247.63M
PS Ratio
137.95
TTM Avg
23.96
3Y Avg
48.69
5Y Avg
88.66
Market Cap
$248.27M
PS Ratio
154.68
TTM Avg
93.71
3Y Avg
139.93
5Y Avg
235.80
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $243.16M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 1.88 | 1.67 | 1.36 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.54M | 57.53 | 46.85 | 41.58 | 41.58 |
| Century Therapeutics, Inc. (IPSC)vs › | $246.26M | N/A | 0.95 | 38.57 | 83.32 |
| Galectin Therapeutics Inc. (GALT)vs › | $241.69M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.63M | 137.95 | 23.96 | 48.69 | 88.66 |
| Quantum-Si incorporated (QSI)vs › | $248.27M | 154.68 | 93.71 | 139.93 | 235.80 |
| Upstream Bio, Inc. (UPB)vs › | $248.43M | 78.67 | 269.20 | 290.37 | 290.37 |
| Q32 Bio Inc. (QTTB)vs › | $238.71M | 4.44 | 2.76 | 7.83 | 16.13 |
| Invivyd, Inc. (IVVD)vs › | $238.48M | 4.09 | 5.57 | 10.86 | 10.86 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-01 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-04 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
